The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
5 citations
,
December 2015 in “PubMed” Some gonadal hormone drugs can block filovirus entry into cells.
December 2023 in “Magna Scientia Advanced Research and Reviews” The document suggests using trazodone and clomiphene to treat sexual dysfunction caused by post-finasteride syndrome.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
3 citations
,
November 1998 in “PubMed” 22 citations
,
May 2003 in “Planta Medica” Torilin from Torilis japonica can inhibit testosterone 5α-reductase but is less effective than finasteride.
49 citations
,
December 1997 in “Urology” Tamoxifen effectively treats gynecomastia without causing impotence.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
April 2010 in “Nature Reviews Urology”
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
December 2013 in “Estudo Geral (Universidade de Coimbra)” Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
May 1993 in “Drugs & Therapy Perspectives” Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.
May 2013 in “UTUPub (University of Turku)” Including androgens in hormone therapy may lower breast cancer risk.
April 2014 in “The FASEB Journal” Testosterone reduces knee movement, while flutamide and finasteride increase it.
December 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” A new combination of tadalafil and finasteride improves drug performance and stability.
1 citations
,
January 2010 in “Endocrine abstracts” Testosterone undecanoate can reduce the negative effects of Finasteride on male reproductive health.
May 2023 in “Frontiers in Endocrinology” Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.
December 2025 in “Molecular Pharmaceutics” Combining tadalafil and finasteride improves their solubility and effectiveness.
2 citations
,
January 2013 in “Iraqi journal of Medical Sciences” 14 citations
,
October 2015 in “Neurochemistry International” Letrozole may help prevent seizures by reducing certain hormone levels.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
2 citations
,
January 2011 in “Springer eBooks” Finasteride is a medicine used to treat enlarged prostate and prostate cancer, and it works by changing how testosterone works in the body.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
51 citations
,
February 2010 in “Analytical and Bioanalytical Chemistry” Researchers developed a method to detect hormone-blocking drugs in wastewater and found them in Beijing's sewage, suggesting they can survive sewage treatment.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
36 citations
,
October 2009 in “Journal of biological chemistry/The Journal of biological chemistry” Two new compounds were found to build bone and muscle without affecting reproductive organs and skin oil glands.
Finasteride may improve prostate cancer therapy by enhancing testosterone's benefits and reducing risks.
17 citations
,
June 1996 in “The Journal of Steroid Biochemistry and Molecular Biology” FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.